[Clinical trial od Di-n-propylacetate in epileptics with therapy-resistant absences].
The clinical trials of Di-n-propylacetate (Depakine, Labaz) produced favorable results with 15 patients, whose epilepsies were characterized by exceptional therapy-resistant absences, partly in combination with grand mal (4 patients). After discontinuation of DPA and renewed application of this drug at a later stage the patients made a good recovery.